Product Data Sheet

Product Name: SNX3-IN-1
Cat. No.: GC81346

Chemical Properties

Cas. No.	2344793-72-0		
Formula	$C_{23}H_{24}O_6$	M.Wt	396.43
Solubility	DMSO: 50 mg/mL (126.13 mM; Need ultrasonic)	Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Structure



Background

SNX3-IN-1 is a sorting nexin 3 (SNX3) inhibitor. SNX3-IN-1 reduces SNX3 protein expression and inhibits SNX3 -mediated activation of the Wnt/β-catenin signaling pathway. SNX3-IN-1 inhibits the proliferation and migration of pulmonary fibrosis-related cells, and decreases the expression of fibrosis markers α-SMA and COL-1. SNX3-IN-1 can be used in research related to pulmonary fibrosis [1].

In Vivo, SNX3-IN-1 (Compound LC4) (10 mg/kg; intratracheal administration; once weekly for 3 consecutive weeks) effectively ameliorates Wnt/β-catenin pathway activation, pulmonary function impairment and fibrosis in a mouse model of pulmonary fibrosis[1].

In Vitro, SNX3-IN-1 (Compound LC4) inhibits the enhanced migratory capacity of fibroblasts overexpressing SNX3[1]. SNX3-IN-1 inhibits SNX3-induced β-catenin accumulation and nuclear

localization in cells[1]. SNX3-IN-1 (10 μM) inhibits TGF-β1-induced α-SMA expression in AT2 cells and fibroblasts, thereby reducing fibrotic activation[1].

References:

[1]. Ma D, et al. Targeting sorting nexin 3 to treat pulmonary fibrosis by dual modulating Wnt/β-catenin signaling. Cell Death Dis. 2026;17(1):43. Published 2026 Jan 15.